MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Day One Biopharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

7.56 2.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.24

Max

7.56

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.7M

-30M

Verkäufe

3.1M

34M

Gewinnspanne

-89.424

Angestellte

182

EBITDA

5.2M

-35M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+218.49% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

29. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

33M

716M

Vorheriger Eröffnungskurs

5.26

Vorheriger Schlusskurs

7.56

Nachrichtenstimmung

By Acuity

50%

50%

183 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Okt. 2025, 16:58 UTC

Ergebnisse

BMW Trims 2025 View, Citing Weaker Performance in China

7. Okt. 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7. Okt. 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7. Okt. 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7. Okt. 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7. Okt. 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 20:44 UTC

Heiße Aktien

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7. Okt. 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7. Okt. 2025, 19:23 UTC

Akquisitionen, Fusionen, Übernahmen

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7. Okt. 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7. Okt. 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Okt. 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7. Okt. 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7. Okt. 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7. Okt. 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7. Okt. 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7. Okt. 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Okt. 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7. Okt. 2025, 14:52 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer-Vergleich

Kursveränderung

Day One Biopharmaceuticals Inc Prognose

Kursziel

By TipRanks

218.49% Vorteil

12-Monats-Prognose

Durchschnitt 23.25 USD  218.49%

Hoch 34 USD

Tief 16 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Day One Biopharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

9

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

6.26 / 7.47Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

183 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
help-icon Live chat